LEADING A NEW PARADIGM IN CARDIOVASCULAR DISEASE MANAGEMENT
Amarin Corporation is focused on a BOLD vision to stop heart disease from being a leading cause of death. Our lead commercial product, VASCEPA® (icosapent ethyl), creates a new paradigm in cardiovascular disease management and is positioned to address cardiovascular risk for millions of patients globally.
The efficacy and safety profile of VASCEPA, as demonstrated in the landmark REDUCE-IT® cardiovascular outcomes study, has been heralded as one of the most significant breakthroughs in preventative cardiovascular care since statin therapy was introduced nearly three decades ago. VASCEPA is supported by over 100 scientific publications and presentations and recommended for use in appropriate at-risk patients by leading medical societies from around the world, including the United States and Europe. The REDUCE-IT results stand in stark contrast to earlier generation drugs, the clinical studies of which failed to show reduction of persistent cardiovascular risk in their studied populations.
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwrig...
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
Aug 28, 2022
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at...
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
Aug 26, 2022
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congres...
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
Aug 15, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgro...